Is GRFS or TYRA more profitable?

Grifols has a net margin of 5.54% compared to Tyra Biosciences' net margin of 0.00%. Grifols' return on equity of 6.21% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Tyra Biosciences N/A -46.39% -43.07%

Does the media prefer GRFS or TYRA?

In the previous week, Tyra Biosciences had 2 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Tyra Biosciences and 1 mentions for Grifols. Grifols' average media sentiment score of 0.95 beat Tyra Biosciences' score of 0.60 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or TYRA?

In the previous week, Iovance Biotherapeutics had 46 more articles in the media than Tyra Biosciences. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 3 mentions for Tyra Biosciences. Iovance Biotherapeutics' average media sentiment score of 0.71 beat Tyra Biosciences' score of 0.60 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 12 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ERAS or TYRA?

Erasca is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A

Is ERAS or TYRA more profitable?

Erasca's return on equity of -38.43% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Tyra Biosciences N/A -46.39% -43.07%

Does the media prefer ERAS or TYRA?

In the previous week, Erasca and Erasca both had 3 articles in the media. Tyra Biosciences' average media sentiment score of 0.60 beat Erasca's score of 0.18 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TYRA or DNTH?

In the previous week, Tyra Biosciences had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 3 mentions for Tyra Biosciences and 2 mentions for Dianthus Therapeutics. Tyra Biosciences' average media sentiment score of 0.60 beat Dianthus Therapeutics' score of 0.15 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, EWTX or TYRA?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A

Is EWTX or TYRA more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Tyra Biosciences N/A -46.39% -43.07%

Does the media favor EWTX or TYRA?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.60 beat Edgewise Therapeutics' score of 0.52 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tyra Biosciences (TYRA) Competitors

$20.43 -0.58 (-2.76%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$20.42 -0.01 (-0.05%)

As of 10/2/2026 07:30 PM Eastern

Compare

TYRA vs. GRFS, IOVA, ERAS, DNTH, and EWTX

Should you buy Tyra Biosciences stock or one of its competitors? Tyra Biosciences's main competitors and comparable companies include Grifols (GRFS), Iovance Biotherapeutics (IOVA), Erasca (ERAS), Dianthus Therapeutics (DNTH), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tyra Biosciences compare to Grifols?

Grifols (NASDAQ:GRFS) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Grifols has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.58	$454.82M	$0.19	38.47
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

In the previous week, Tyra Biosciences had 2 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Tyra Biosciences and 1 mentions for Grifols. Grifols' average media sentiment score of 0.95 beat Tyra Biosciences' score of 0.60 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols currently has a consensus price target of $10.00, indicating a potential upside of 36.80%. Tyra Biosciences has a consensus price target of $46.89, indicating a potential upside of 129.51%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Grifols has a net margin of 5.54% compared to Tyra Biosciences' net margin of 0.00%. Grifols' return on equity of 6.21% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Tyra Biosciences	N/A	-46.39%	-43.07%

84.1% of Tyra Biosciences shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Grifols has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Summary

Grifols and Tyra Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Iovance Biotherapeutics currently has a consensus target price of $12.40, indicating a potential downside of 12.80%. Tyra Biosciences has a consensus target price of $46.89, indicating a potential upside of 129.51%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tyra Biosciences has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Tyra Biosciences	N/A	-46.39%	-43.07%

Iovance Biotherapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 46 more articles in the media than Tyra Biosciences. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 3 mentions for Tyra Biosciences. Iovance Biotherapeutics' average media sentiment score of 0.71 beat Tyra Biosciences' score of 0.60 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	12 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tyra Biosciences has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.44	-$390.98M	-$0.73	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Summary

Tyra Biosciences beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Erasca?

Erasca (NASDAQ:ERAS) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Erasca's return on equity of -38.43% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Tyra Biosciences	N/A	-46.39%	-43.07%

67.8% of Erasca shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Erasca is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Erasca presently has a consensus price target of $22.09, indicating a potential upside of 49.87%. Tyra Biosciences has a consensus price target of $46.89, indicating a potential upside of 129.51%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Erasca and Erasca both had 3 articles in the media. Tyra Biosciences' average media sentiment score of 0.60 beat Erasca's score of 0.18 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Summary

Tyra Biosciences beats Erasca on 9 of the 13 factors compared between the two stocks.

How does Tyra Biosciences compare to Dianthus Therapeutics?

Tyra Biosciences (NASDAQ:TYRA) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Tyra Biosciences has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Tyra Biosciences has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Dianthus Therapeutics	$2.04M	2,369.56	-$162.34M	-$4.15	N/A

Tyra Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Tyra Biosciences currently has a consensus target price of $46.89, suggesting a potential upside of 129.51%. Dianthus Therapeutics has a consensus target price of $129.83, suggesting a potential upside of 47.19%. Given Tyra Biosciences' higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Tyra Biosciences had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 3 mentions for Tyra Biosciences and 2 mentions for Dianthus Therapeutics. Tyra Biosciences' average media sentiment score of 0.60 beat Dianthus Therapeutics' score of 0.15 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Tyra Biosciences beats Dianthus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Edgewise Therapeutics' return on equity of -39.01% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Tyra Biosciences	N/A	-46.39%	-43.07%

Edgewise Therapeutics currently has a consensus price target of $51.33, suggesting a potential upside of 23.99%. Tyra Biosciences has a consensus price target of $46.89, suggesting a potential upside of 129.51%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

84.1% of Tyra Biosciences shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.60 beat Edgewise Therapeutics' score of 0.52 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Summary

Tyra Biosciences beats Edgewise Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.22B	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-8.51	13.06	275.66	26.04
Price / Sales	N/A	1,295.73	609.44	91.76
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	4.20	16.63	10.93	6.31
Net Income	-$119.95M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-6.11%	-2.99%	-2.00%	-1.66%
1 Month Performance	-17.82%	-10.60%	-6.15%	-4.50%
1 Year Performance	49.56%	19.44%	7.44%	2.06%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	3.3501 of 5 stars	$20.43 -2.8%	$46.89 +129.5%	+52.6%	$1.22B	N/A	N/A	87
GRFS Grifols	4.7876 of 5 stars	$7.30 -1.5%	$10.00 +37.0%	-27.0%	$5.04B	$8.51B	38.42	25,247	News Coverage
IOVA Iovance Biotherapeutics	1.7015 of 5 stars	$14.45 +31.5%	$11.78 -18.5%	+532.0%	$4.98B	$263.50M	N/A	975	Trending News Analyst Forecast Analyst Revision High Trading Volume
ERAS Erasca	2.1342 of 5 stars	$14.21 +0.6%	$22.09 +55.5%	+592.0%	$4.94B	N/A	N/A	103
DNTH Dianthus Therapeutics	2.0344 of 5 stars	$87.16 -0.8%	$129.83 +49.0%	+138.9%	$4.81B	$2.04M	N/A	92

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. GRFS, IOVA, ERAS, DNTH, and EWTX

How does Tyra Biosciences compare to Grifols?

Summary

How does Tyra Biosciences compare to Iovance Biotherapeutics?

Summary

How does Tyra Biosciences compare to Erasca?

Summary

How does Tyra Biosciences compare to Dianthus Therapeutics?

Summary

How does Tyra Biosciences compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. GRFS, IOVA, ERAS, DNTH, and EWTX

How does Tyra Biosciences compare to Grifols?

Which has better valuation and earnings, GRFS or TYRA?

Does the media prefer GRFS or TYRA?

Do analysts recommend GRFS or TYRA?

Is GRFS or TYRA more profitable?

Do insiders and institutionals have more ownership in GRFS or TYRA?

Which has more risk & volatility, GRFS or TYRA?

Summary

How does Tyra Biosciences compare to Iovance Biotherapeutics?

Do analysts prefer IOVA or TYRA?

Is IOVA or TYRA more profitable?

Which has more volatility & risk, IOVA or TYRA?

Does the media refer more to IOVA or TYRA?

Do insiders & institutionals believe in IOVA or TYRA?

Which has stronger earnings & valuation, IOVA or TYRA?

Summary

How does Tyra Biosciences compare to Erasca?

Is ERAS or TYRA more profitable?

Do insiders & institutionals believe in ERAS or TYRA?

Which has higher valuation & earnings, ERAS or TYRA?

Do analysts rate ERAS or TYRA?

Does the media prefer ERAS or TYRA?

Which has more risk & volatility, ERAS or TYRA?

Summary

How does Tyra Biosciences compare to Dianthus Therapeutics?

Is TYRA or DNTH more profitable?

Which has better earnings and valuation, TYRA or DNTH?

Which has more risk and volatility, TYRA or DNTH?

Do analysts recommend TYRA or DNTH?

Does the media refer more to TYRA or DNTH?

Do institutionals & insiders hold more shares of TYRA or DNTH?

Summary

How does Tyra Biosciences compare to Edgewise Therapeutics?

Which has higher valuation and earnings, EWTX or TYRA?

Is EWTX or TYRA more profitable?

Do analysts prefer EWTX or TYRA?

Do institutionals & insiders hold more shares of EWTX or TYRA?

Does the media favor EWTX or TYRA?

Which has more volatility & risk, EWTX or TYRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools